PHC Holdings Corporation
PHC Holdings Corporation First Quarter IFRS Consolidated Financial Results Report (IFRS)
For the first quarter of the fiscal year ending March 2027, consolidated net sales were 90,672 million yen (YoY +8.1%), operating income was 10,413 million yen (+171.0% YoY), and net income for the period was 6,293 million yen, indicating solid performance. Segments such as Diabetes Management, Clinical Testing & CRO, and Pathology & Life Sciences contributed. Full-year guidance unchanged.
Key Figures
- Net sales: 90,672百万円
- Operating income: 10,413百万円
- Net income attributable to owners of the parent: 6,338百万円
AI要約
Performance overview
This quarter posted net sales of 90,672 million yen (YoY +8.1%) and operating income of 10,413 million yen (YoY +171.0%), marking a substantial profit increase. By segment, Diabetes Management, Clinical Testing & CRO, and Pathology & Life Sciences showed solid momentum, supported by foreign exchange effects and cost reductions. Equity in earnings of affiliates was -28 million yen, net income for the period was 6,293 million yen, and net income attributable to owners of the parent turned positive to 6,338 million yen.
Outlook and material matters
For the full-year fiscal year ending March 2027, there is no revision to the latest outlook; the current assumptions are kept. As drivers of segment strength, demand recovery, price revisions, and exchange rate effects in the U.S., Europe, and developing markets are expected to continue. Preparation of the earnings supplement materials and an earnings briefing are planned.
PHC Holdings Corporation
Company overview · Stock price · Financial data · All IR
